<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Atopic keratoconjunctivitis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Atopic keratoconjunctivitis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Atopic keratoconjunctivitis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Pedram Hamrah, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Reza Dana, MD, MPH, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Deborah S Jacobs, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna M Feldweg, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atopic keratoconjunctivitis (AKC) is a chronic, allergic ocular disease that occurs most often in adults with a history of atopic dermatitis (AD). Although less common than other forms of ocular allergy, AKC can cause severe damage to the ocular surface, leading to corneal scarring and vision loss if not treated properly.
        </p>
        <p>
         The clinical manifestations, pathogenesis, diagnosis, and treatment of AKC are reviewed here. Other forms of allergic ocular disease are discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5547.html" rel="external">
          "Allergic conjunctivitis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5549.html" rel="external">
          "Vernal keratoconjunctivitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5553.html" rel="external">
          "Giant papillary conjunctivitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         AKC is a chronic, perennial eye disease that typically occurs in patients with a history of atopic dermatitis (AD) [
         <a href="#rid1">
          1,2
         </a>
         ]. The exact prevalence is unknown, although approximately 4 percent of patients with ocular allergy had AKC in one large study [
         <a href="#rid3">
          3
         </a>
         ]. Among patients with AD, studies have reported varying estimates of how many patients also have AKC, ranging from 20 to 77 percent [
         <a href="#rid4">
          4,5
         </a>
         ]. Approximately 5 percent of patients with AKC do not have AD [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
         AKC usually begins in late adolescence or early adulthood, with a peak incidence between 30 and 50 years of age. However, onset of symptoms of AKC has been described between 7 and 76 years of age. AKC has a male:female ratio of 2.4:1 [
         <a href="#rid1">
          1
         </a>
         ]. Personal and family histories are almost always positive for atopy (more commonly AD and asthma than allergic rhinitis) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         AKC consists of type IV (delayed-type) hypersensitivity reactions and some involvement of type I hypersensitivity.
        </p>
        <p>
         Tears in patients with AKC contain CD4+ T cells and B cells and increased levels of the cytokines interferon gamma, tumor necrosis factor alpha, interleukin (IL) 4, IL-5, and IL-10 and the chemokine eotaxin compared with normal controls [
         <a href="#rid8">
          8-11
         </a>
         ]. Patients with AKC may show dysfunctional cell-mediated immunity and occasionally have lower levels of circulating T cells [
         <a href="#rid12">
          12
         </a>
         ], although this is not used in diagnosis. Elevated levels of immunoglobulin E (IgE) are observed in the tears and serum of AKC patients compared with normal controls [
         <a href="#rid13">
          13
         </a>
         ]. Allergy testing identifies specific sensitivities in approximately one-half of patients [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         On histology, the conjunctival epithelial layer is thickened in AKC. The conjunctival epithelium and substantia propria of AKC patients show elevated numbers of mast cells and eosinophils, increased fibroblast numbers and collagen amount, and an increased CD4+:CD8+ ratio of T cells compared with normal individuals [
         <a href="#rid8">
          8,13-15
         </a>
         ]. In addition, large numbers of mononuclear cells are present in the substantia propria.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3715213964">
         <span class="h2">
          Symptoms and signs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most commonly reported symptom of AKC is intense itching, which usually occurs perennially, although some patients report seasonal exacerbations [
         <a href="#rid1">
          1,13
         </a>
         ]. Tearing, burning, clear mucus discharge, and redness are also almost always present. Other symptoms include blurry vision, photophobia, and foreign body sensation. Most patients rub their eyes incessantly. Chronic ocular surface inflammation can lead to vision loss.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Physical findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         AKC can involve the eyelid, conjunctiva, and cornea [
         <a href="#rid1">
          1,2,16
         </a>
         ]. There is a wide range of severity, from mild, isolated eyelid involvement to sight-threatening corneal involvement. Both eyes are usually involved, although the severity may be asymmetric.
        </p>
        <p>
         Eyelid changes in AKC are usually quite striking (
         <a class="graphic graphic_picture graphicRef56670" href="/z/d/graphic/56670.html" rel="external">
          picture 1
         </a>
         ). Characteristic findings include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thickened eyelids
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermittent swelling of the eyelids due to chronic inflammation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A scaly and indurated appearance to the periocular skin, with flaking dermatitis and a reddened base
        </p>
        <p>
        </p>
        <p>
         Eyelids may become lichenified and woody, developing cicatricial ectropion (lower eyelid turns outward or everts due to scarring) and lagophthalmos (failure to close the eyelids completely). Fissures, loss of eyelashes, lateral canthal ulceration, and ptosis can sometimes develop as well. Eyelid margins may show meibomianitis, keratinization, and punctal ectropion (lacrimal puncta are everted). Coexisting blepharitis caused by staphylococcal bacteria is also common. Over time, the periorbital skin may become hyperpigmented (
         <a class="graphic graphic_picture graphicRef108137" href="/z/d/graphic/108137.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2334874065">
         <span class="h2">
          Manifestations of chronic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Manifestations of chronic disease include dry eyes (
         <a class="graphic graphic_picture graphicRef62824" href="/z/d/graphic/62824.html" rel="external">
          picture 3
         </a>
         ), corneal neovascularization (
         <a class="graphic graphic_picture graphicRef69396" href="/z/d/graphic/69396.html" rel="external">
          picture 4
         </a>
         ), and sterile ulcers.
        </p>
        <p class="headingAnchor" id="H2968853104">
         <span class="h2">
          Associated and complicating conditions
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infectious and herpetic ulcers
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ocular infection with
         <em>
          Staphylococcus aureus
         </em>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Corneal thinning disorders (eg, keratoconus) and corneal perforation [
         <a href="#rid17">
          17
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retinal detachment (presenting with symptoms of increased floaters, flashes, or black curtains in the eye) (see
         <a class="medical medical_review" href="/z/d/html/6902.html" rel="external">
          "Approach to the adult with acute persistent visual loss", section on 'Retinal detachment'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2390298014">
         <span class="h1">
          EVALUATION AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis should be suspected in a patient with a history of atopic dermatitis (AD) who presents with ocular itching and eyelid dermatitis. Generalists should examine the skin, eyes, and eyelids. AKC is typically bilateral, so unilateral disease should prompt consideration of other disorders.
        </p>
        <p>
         A general skin examination should be performed if the diagnosis of AD (eczema) has not already been established. Dry skin and severe itching are the cardinal signs of AD. Acute AD is characterized by intensely itchy erythematous papules and vesicles with exudation and crusting, whereas subacute or chronic lesions present as dry, scaly, or excoriated erythematous papules (
         <a class="graphic graphic_picture graphicRef80481" href="/z/d/graphic/80481.html" rel="external">
          picture 5
         </a>
         ). Skin thickening from chronic scratching (lichenification) and fissuring may develop over time (
         <a class="graphic graphic_picture graphicRef55375" href="/z/d/graphic/55375.html" rel="external">
          picture 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1729.html" rel="external">
          "Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3300328460">
         <span class="h2">
          When to refer
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with suspected AKC, regardless of severity, should be referred to an ophthalmologist. Every patient requires a thorough ophthalmologic examination to ensure that corneal and conjunctival pathology, in particular, is identified and managed appropriately. A thorough slit-lamp examination of the cornea, bulbar, and palpebral conjunctiva will be performed by the ophthalmologist. In moderate-to-severe cases, patients are then referred to a cornea and external disease specialist.
        </p>
        <p class="headingAnchor" id="H1367406321">
         <span class="h2">
          Ocular examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Definitive diagnosis is made by an ophthalmologist based on characteristic signs and symptoms. There are no established diagnostic criteria or laboratory tests for AKC.
        </p>
        <p>
         Signs of chronic ocular surface inflammation include (
         <a class="graphic graphic_picture graphicRef69396" href="/z/d/graphic/69396.html" rel="external">
          picture 4
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conjunctival chemosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conjunctival hyperemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tarsal papillary hypertrophy
        </p>
        <p>
        </p>
        <p>
         Upon slit-lamp evaluation, the papillary hypertrophy in AKC is most prominent in the inferior fornix. In addition, papillae may form adjacent to the cornea as perilimbal gelatinous hyperplasia. Subepithelial fibrosis is common, but forniceal shortening and symblepharon (adhesion of the eyelid to the globe) may also form.
        </p>
        <p>
         Giant papillae may be detected on the conjunctival lining of the lower tarsus and inferior fornix. Giant papillae may also be present on the conjunctival lining of the upper eyelids. However, this finding is common in many other ocular diseases and with contact lens use or foreign body (eg, exposed suture), so, if the majority of the papillae are on the upper eyelids, these other conditions should be considered.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are four other main types of ocular allergy: seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis (VKC), and giant papillary conjunctivitis. Of these, VKC is the primary disorder in the differential diagnosis of AKC. Other disorders that may resemble mild AKC include toxic conjunctivitis, blepharitis, and rosacea.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VKC
         </strong>
         – VKC most often occurs in prepubertal boys from warm climates. The peak incidence of VKC is between 7 and 12 years of age. Symptoms are most often seasonal initially, and the upper tarsus (eyelid) is predominantly affected. In contrast, AKC usually affects adults, and symptoms are present perennially, although there may be seasonal exacerbations if the patient has coexisting seasonal allergies. Patients with VKC often develop giant papillae on the conjunctival lining of the upper eyelid, whereas the papillary hypertrophy in AKC is more prominent in the inferior fornix. Both VKC and AKC can affect the cornea and threaten sight, and referral to an ophthalmologist is indicated. VKC is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5549.html" rel="external">
          "Vernal keratoconjunctivitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxic conjunctivitis
         </strong>
         – Toxic conjunctivitis is not allergic in nature, but it is frequently confused with allergic ocular disease. It develops with protracted use of topical medications, mostly due to preservatives. It is not associated with atopic dermatitis (AD). This disorder is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5555.html" rel="external">
          "Toxic conjunctivitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blepharitis
         </strong>
         – Blepharitis is a common inflammatory disorder of the eyelids, which presents with chronic eye irritation, often accompanied by eye redness (
         <a class="graphic graphic_picture graphicRef64540" href="/z/d/graphic/64540.html" rel="external">
          picture 7
         </a>
         ). Characteristic waxy scaling in the eyelashes may be present. Symptoms may flare episodically. Blepharitis is associated with seborrhea and facial rosacea, whereas most patients with AKC have AD. (See
         <a class="medical medical_review" href="/z/d/html/6915.html" rel="external">
          "Blepharitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ocular rosacea
         </strong>
         – Ocular rosacea presents with burning, itching, foreign body sensation, dryness, tearing, or photophobia. The most common findings in patients with ocular rosacea are blepharitis, eyelid margin telangiectasias, and conjunctival hyperemia. Some patients may have cutaneous rosacea (erythematous rash and telangiectasias in the malar areas), but others may not. The eyelids in patients with rosacea are erythematous, whereas the eyelids in AKC are more thickened and hyperpigmented.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H183404544">
         <span class="h1">
          COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complications of AKC include several forms of cataracts, which may result from AKC itself or from corticosteroid therapy. Vision loss may result from corneal scarring and chronic corneal ulceration. Other less predictable complications are discussed above. (See
         <a class="local">
          'Associated and complicating conditions'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of AKC includes basic eye care as well as topical and sometimes systemic medications. Our approach in adults and children is similar, although data in children are lacking [
         <a href="#rid18">
          18-20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1798797571">
         <span class="h2">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients should be evaluated by an ophthalmologist and counseled in basic eye care. We usually begin treatment with dual-action agents (ie, agents with both mast cell-stabilizing and antihistamine actions). If symptoms do not improve sufficiently, a brief course of topical corticosteroids is the next step. For patients who have trouble controlling symptoms when topical corticosteroids are reduced, we add topical calcineurin inhibitors as steroid-sparing agents. Most patients have adequate control with these measures over time, but a small percentage require systemic immunosuppressive therapies.
        </p>
        <p class="headingAnchor" id="H3460975263">
         <span class="h2">
          Basic eye care
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several general measures that are helpful to most patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients should not rub their eyes, because rubbing can cause mechanical mast cell degranulation and worsening of symptoms, which requires thorough patient education.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cool compresses can help reduce eyelid and periorbital edema.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Frequent use of refrigerated
         <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">
          artificial tears
         </a>
         throughout the day can help patients with concomitant dry eye.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3751446308">
         <span class="h2">
          Mild disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary topical agents used in mild AKC are antihistamines with mast cell-stabilizing properties, corticosteroids, and calcineurin inhibitors.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Antihistamines/mast cell stabilizers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical antihistamines with mast cell-stabilizing properties are typically used as daily, long-term prophylactic therapy based on their efficacy in other allergic eye diseases. Stabilization of mast cells prevents release of histamine and other proinflammatory mediators from mast cells in the ocular tissues. There are no randomized trials or observational studies using these drugs in AKC. Specific medications include
         <a class="drug drug_general" data-topicid="10177" href="/z/d/drug information/10177.html" rel="external">
          olopatadine
         </a>
         (Patanol, Pataday, Pazeo [brand names]),
         <a class="drug drug_general" data-topicid="15587" href="/z/d/drug information/15587.html" rel="external">
          alcaftadine
         </a>
         (Lastacaft [brand name]),
         <a class="drug drug_general" data-topicid="8819" href="/z/d/drug information/8819.html" rel="external">
          bepotastine
         </a>
         (Bepreve [brand name]),
         <a class="drug drug_general" data-topicid="8798" href="/z/d/drug information/8798.html" rel="external">
          azelastine
         </a>
         hydrochloride (Optivar [brand name]),
         <a class="drug drug_general" data-topicid="8601" href="/z/d/drug information/8601.html" rel="external">
          epinastine
         </a>
         (Elestat [brand name]),
         <a class="drug drug_general" data-topicid="16764" href="/z/d/drug information/16764.html" rel="external">
          ketotifen
         </a>
         fumarate (generic, Ketotifen [brand name]), and
         <a class="drug drug_general" data-topicid="8778" href="/z/d/drug information/8778.html" rel="external">
          emedastine
         </a>
         (Emadine [brand name]). Ketotifen fumarate and olopatadine are available without a prescription (in the United States).
        </p>
        <p>
         Dosing is twice per day for most products. Pataday, Pazeo, and Lastacaft (brand names) are once-daily preparations. It may take two to three weeks to see the full effect of these agents and for symptoms to subside.
        </p>
        <p>
         Common side effects include stinging and burning upon instillation. Patients may find it helpful to refrigerate the drops and/or use refrigerated
         <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">
          artificial tears
         </a>
         before using these medications. Other adverse effects include headache and increased ocular dryness.
        </p>
        <p class="headingAnchor" id="H755401439">
         <span class="h2">
          Additional therapies for resistant disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional therapies for symptoms that persist despite a mast cell stabilizer/antihistamine include topical corticosteroids and calcineurin inhibitors.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Topical corticosteroids
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who do not respond to two or three weeks of consistent therapy with a mast cell stabilizer/antihistamine, pulse therapy with topical corticosteroids is appropriate. Topical corticosteroids are used to gain control of the inflammation so that mast cell stabilizers/antihistamines and
         <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">
          artificial tears
         </a>
         have a greater chance of working. Patients should be referred to an ophthalmologist for this therapy as it should be monitored carefully and only used for brief periods of time. Long-term use of topical corticosteroids increases the risk of cataract formation, glaucoma, and serious eye infections (eg, herpes keratitis).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For mild-to-moderate symptoms, we suggest one of several "soft" ester steroids, such as
         <a class="drug drug_general" data-topicid="10116" href="/z/d/drug information/10116.html" rel="external">
          loteprednol
         </a>
         0.5 or 0.2%,
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         acetate 0.12%,
         <a class="drug drug_general" data-topicid="8463" href="/z/d/drug information/8463.html" rel="external">
          fluorometholone
         </a>
         ointment, and
         <a class="drug drug_general" data-topicid="9867" href="/z/d/drug information/9867.html" rel="external">
          rimexolone
         </a>
         1%. We prefer loteprednol etabonate 0.5%, applied twice per day for two weeks. Greater than six weeks of use is associated with an increased risk of complications. The soft steroids undergo rapid inactivation upon penetration of the cornea and have decreased ocular penetration. They are therefore less likely to cause elevations of intraocular pressure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For severe symptoms, we use
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         acetate (1% suspension), eight times per day for approximately one week. This can be reduced to four times daily and then tapered slowly with close follow-up.
        </p>
        <p>
        </p>
        <p>
         Data on the efficacy of topical corticosteroids in treating AKC are limited. In a double-blind trial of 38 patients with AKC, topical 2% sodium cromoglycate (a mast cell stabilizer without antihistamine properties) was applied every six hours in one eye and 1% medrysone in the contralateral eye for four weeks [
         <a href="#rid21">
          21
         </a>
         ]. Medrysone (discontinued in the United States) significantly improved itching, watering, photophobia, and hyperemia, whereas
         <a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">
          cromolyn
         </a>
         had little effect.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Topical calcineurin inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical calcineurin inhibitors are also used for refractory symptoms. They have the advantage of not increasing intraocular pressure [
         <a href="#rid22">
          22
         </a>
         ]. However, they act more slowly than topical corticosteroids, and the availability of these agents often limits their use. Four preparations (two different
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ophthalmic 0.05% solutions, a cyclosporine ophthalmic 0.09% solution, as well as a cyclosporine ophthalmic 0.1% solution) are commercially available in the United States. Preparations of cyclosporine (1 and 2% solutions) and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         (0.03% solution) can be compounded. Adverse effects include stinging and eyelid maceration. (See
         <a class="medical medical_review" href="/z/d/html/5549.html" rel="external">
          "Vernal keratoconjunctivitis", section on 'Calcineurin inhibitors'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Trial data are limited. In one small, randomized trial, topical
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         (2% four times daily) was more effective than placebo in reducing topical corticosteroid use and improving signs and symptoms in patients with AKC [
         <a href="#rid23">
          23
         </a>
         ]. In a subsequent cohort study, topical cyclosporine 0.1% significantly reduced the frequency of inflammatory episodes, need for concomitant topical corticosteroids, and clinic visits in patients with AKC [
         <a href="#rid24">
          24
         </a>
         ]. We prefer higher doses (2% cyclosporine) to the commercially available 0.05% cyclosporine solution, as lower concentrations of cyclosporine have shown mixed efficacy [
         <a href="#rid25">
          25-28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence for the efficacy of
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         is limited to case series. In a series of 30 children and young adults with severe AKC refractory to topical corticosteroids, 0.1% tacrolimus suspension was effective over the course of one year in controlling symptoms and allowing for reduction in corticosteroid dose [
         <a href="#rid29">
          29
         </a>
         ]. Three cases of herpetic keratitis developed during treatment but were managed successfully with antiviral medications. In a smaller study of five patients with severe AKC, continuous therapy with topical tacrolimus led to significant improvement as well [
         <a href="#rid30">
          30
         </a>
         ]. Topical tacrolimus ointment has also been used to treat associated eyelid eczema [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Systemic immunosuppressive agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic immunosuppressive agents (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ) are sometimes used in severe cases in which topical corticosteroids are ineffective or are required for longer than six weeks. Three small case series found that long-term therapy with oral calcineurin inhibitors (cyclosporine, 3 to 5 mg/kg daily or tacrolimus, 0.03 to 0.08 mg/kg daily) was generally safe and resulted in complete remission in most patients with severe, refractory AKC [
         <a href="#rid32">
          32,33
         </a>
         ]. Comanagement with an ophthalmologist, internist, allergist, dermatologist, and/or rheumatologist is recommended to maximize the outcome and minimize side effects in these difficult cases.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Other therapies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral, nonsedating antihistamines, including
         <a class="drug drug_general" data-topicid="8445" href="/z/d/drug information/8445.html" rel="external">
          fexofenadine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">
          loratadine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8472" href="/z/d/drug information/8472.html" rel="external">
          desloratadine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9443" href="/z/d/drug information/9443.html" rel="external">
          levocetirizine
         </a>
         , have demonstrated efficacy in the treatment of allergic conjunctivitis, although no extensive studies have been performed specifically in patients with AKC. Activation of ocular H1 receptors via histamine is responsible for some AKC symptoms [
         <a href="#rid2">
          2
         </a>
         ], suggesting that oral antihistamines may be helpful. We use oral antihistamines when topical treatment alone does not control itching sufficiently. (See
         <a class="medical medical_review" href="/z/d/html/5549.html" rel="external">
          "Vernal keratoconjunctivitis", section on 'Add-on initial therapy for moderate-to-severe disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Allergen immunotherapy may be helpful for patients with AKC and environmental allergies, based on its efficacy in allergic conjunctivitis and in some patients with atopic dermatitis (AD) [
         <a href="#rid34">
          34
         </a>
         ]. Immunotherapy for AKC specifically has not be studied. Consultation with an allergist for allergy testing and administration of immunotherapy is required. Allergists can also guide measures to limit exposure to the allergens that are relevant to that patient. (See
         <a class="medical medical_review" href="/z/d/html/361.html" rel="external">
          "Subcutaneous immunotherapy (SCIT) for allergic rhinoconjunctivitis and asthma: Indications and efficacy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1617093940">
         <span class="h2">
          Treatment of eyelid dermatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of AKC also involves therapy for eyelid dermatitis. Topical calcineurin inhibitors, such as topical
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         (1%) and
         <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">
          pimecrolimus
         </a>
         (1%) ointments, are preferred because they have fewer long-term side effects [
         <a href="#rid35">
          35-38
         </a>
         ]. In a randomized, crossover trial, there was a nonsignificant trend toward superior benefit of topical tacrolimus in reducing signs and symptoms of eyelid eczema compared with the topical corticosteroid
         <a class="drug drug_general" data-topicid="107874" href="/z/d/drug information/107874.html" rel="external">
          clobetasone
         </a>
         in patients with AKC [
         <a href="#rid35">
          35
         </a>
         ]. Ocular signs and symptoms also improved with topical tacrolimus therapy restricted to the eyelids in several case series [
         <a href="#rid36">
          36,37
         </a>
         ]. Once the symptoms have improved, the frequency of application can be reduced to the lowest dose that maintains symptom control.
        </p>
        <p>
         Low-potency topical corticosteroid ointments, such as
         <a class="drug drug_general" data-topicid="8463" href="/z/d/drug information/8463.html" rel="external">
          fluorometholone
         </a>
         or
         <a class="drug drug_general" data-topicid="10116" href="/z/d/drug information/10116.html" rel="external">
          loteprednol
         </a>
         , are also options for refractory symptoms. These may be applied to the eyelids two to four times per day for several weeks to treat inflamed periocular skin. However, patients should be warned that prolonged use of corticosteroids on the skin can lead to dermal thinning. Additionally, these patients should be monitored by an ophthalmologist for ocular side effects because of the permeability of corticosteroids through the skin.
        </p>
        <p class="headingAnchor" id="H2590805770">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         With therapies, most patient's symptoms can be adequately controlled, and vision impairment or loss is rare.
        </p>
        <p class="headingAnchor" id="H3244817348">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109230.html" rel="external">
          "Society guideline links: Allergic eye disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Atopic keratoconjunctivitis (AKC) is a chronic and aggressive form of ocular allergy that occurs most often in adults with a history of atopic dermatitis (AD). If not treated properly, AKC can damage the ocular surface, leading to corneal scarring, keratoconus due to persistent eye rubbing, and vision loss. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Signs and symptoms
         </strong>
         – AKC is characterized by intense ocular itching, which can occur perennially or only in certain seasons. Most patients rub their eyes incessantly. Tearing, clear mucus discharge, and redness are also almost always present. Other symptoms include blurry vision, burning, photophobia, and foreign body sensation. (See
         <a class="local">
          'Symptoms and signs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical findings
         </strong>
         – AKC involves the eyelid, conjunctiva, and cornea. The eyelids may thicken, swell intermittently, and acquire a scaly and indurated appearance, with flaking dermatitis and a reddened base (
         <a class="graphic graphic_picture graphicRef56670" href="/z/d/graphic/56670.html" rel="external">
          picture 1
         </a>
         ). Ocular findings include conjunctival chemosis and hyperemia. (See
         <a class="local">
          'Physical findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation and referral
         </strong>
         – AKC should be suspected in a patient with a history of AD who presents with ocular itching and eyelid dermatitis. Referral to an ophthalmologist should be pursued in all patients with suspected AKC regardless of severity. The diagnosis is based upon typical epidemiology and clinical features. Routine laboratory tests are not helpful, and there are no established diagnostic criteria. (See
         <a class="local">
          'Evaluation and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment
         </strong>
         – The approach to patients with AKC includes basic eye care, topical medications, and systemic medications, if needed. We suggest a topical, dual-acting antihistamine/mast cell stabilizer as first-line therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Specific medications include
         <a class="drug drug_general" data-topicid="10177" href="/z/d/drug information/10177.html" rel="external">
          olopatadine
         </a>
         (Patanol, Pataday, Pazeo [brand names]),
         <a class="drug drug_general" data-topicid="15587" href="/z/d/drug information/15587.html" rel="external">
          alcaftadine
         </a>
         (Lastacaft [brand name]),
         <a class="drug drug_general" data-topicid="8819" href="/z/d/drug information/8819.html" rel="external">
          bepotastine
         </a>
         (Bepreve [brand name]),
         <a class="drug drug_general" data-topicid="8798" href="/z/d/drug information/8798.html" rel="external">
          azelastine
         </a>
         hydrochloride (Optivar [brand name]),
         <a class="drug drug_general" data-topicid="8601" href="/z/d/drug information/8601.html" rel="external">
          epinastine
         </a>
         (Elestat [brand name]),
         <a class="drug drug_general" data-topicid="16764" href="/z/d/drug information/16764.html" rel="external">
          ketotifen
         </a>
         fumarate (generic, Ketotifen [brand name]), and
         <a class="drug drug_general" data-topicid="8778" href="/z/d/drug information/8778.html" rel="external">
          emedastine
         </a>
         (Emadine [brand name]). (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advanced therapies
         </strong>
         – Additional therapies should be initiated only in consultation with an ophthalmologist:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with AKC who do not improve after two to three weeks of a mast cell stabilizer or dual-acting antihistamine/mast cell stabilizer, we suggest a brief course of topical corticosteroids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Topical corticosteroids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with resistant or moderate-to-severe disease who require frequent or prolonged courses of topical corticosteroids, we suggest topical
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         (2%, compounded) as a steroid-sparing agent (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Topical calcineurin inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of eyelid dermatitis
         </strong>
         – We suggest treating the eyelid dermatitis component of AKC with topical
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         , rather than topical corticosteroids (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Treatment of eyelid dermatitis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Tuft SJ, Kemeny DM, Dart JK, Buckley RJ. Clinical features of atopic keratoconjunctivitis. Ophthalmology 1991; 98:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster CS, Calonge M. Atopic keratoconjunctivitis. Ophthalmology 1990; 97:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uchio E, Kimura R, Migita H, et al. Demographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergy. Graefes Arch Clin Exp Ophthalmol 2008; 246:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moscovici BK, Cesar AS, Nishiwaki-Dantas MC, et al. [Atopic keratoconjunctivitis in patients of the pediatric dermatology ambulatory in a reference center]. Arq Bras Oftalmol 2009; 72:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bielory B, Bielory L. Atopic dermatitis and keratoconjunctivitis. Immunol Allergy Clin North Am 2010; 30:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guglielmetti S, Dart JK, Calder V. Atopic keratoconjunctivitis and atopic dermatitis. Curr Opin Allergy Clin Immunol 2010; 10:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dogru M, Nakagawa N, Tetsumoto K, et al. Ocular surface disease in atopic dermatitis. Jpn J Ophthalmol 1999; 43:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leonardi A, De Dominicis C, Motterle L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol 2007; 7:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy 2006; 36:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leonardi A, Jose PJ, Zhan H, Calder VL. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology 2003; 110:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metz DP, Hingorani M, Calder VL, et al. T-cell cytokines in chronic allergic eye disease. J Allergy Clin Immunol 1997; 100:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braude LS, Chandler JW. Atopic corneal disease. Int Ophthalmol Clin 1984; 24:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonini S. Atopic keratoconjunctivitis. Allergy 2004; 59 Suppl 78:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster CS, Rice BA, Dutt JE. Immunopathology of atopic keratoconjunctivitis. Ophthalmology 1991; 98:1190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soukiasian SH, Rice B, Foster CS, Lee SJ. The T cell receptor in normal and inflamed human conjunctiva. Invest Ophthalmol Vis Sci 1992; 33:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calonge M, Herreras JM. Clinical grading of atopic keratoconjunctivitis. Curr Opin Allergy Clin Immunol 2007; 7:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nivenius E, Montan P. Spontaneous corneal perforation associated with atopic keratoconjunctivitis: a case series and literature review. Acta Ophthalmol 2015; 93:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SE, Nowak V, Quartilho A, et al. Systemic interventions for severe atopic and vernal keratoconjunctivitis in children and young people up to the age of 16 years. Cochrane Database Syst Rev 2020; 10:CD013298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridolo E, Kihlgren P, Pellicelli I, et al. Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly. Drugs Aging 2019; 36:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Luo X, Ke H, Liang L. Recalcitrant Atopic Keratoconjunctivitis in Children: A Case Report and Literature Review. Pediatrics 2018; 141:S470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vajpayee RB, Gupta SK, Uppal RK. Evaluation of sodium cromoglycate and medrysone in the management of atopic keratoconjunctivitis: a double masked clinical study. Aust N Z J Ophthalmol 1986; 14:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abud TB, Amparo F, Saboo US, et al. A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease. Ophthalmology 2016; 123:1449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hingorani M, Moodaley L, Calder VL, et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology 1998; 105:1715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dahlmann-Noor AH, Roberts C, Muthusamy K, et al. Topical cyclosporine A 1 mg/ml for atopic keratoconjunctivitis: Five-year case series of 99 children and young people. Acta Ophthalmol 2023; 101:e197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology 2004; 111:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daniell M, Constantinou M, Vu HT, Taylor HR. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol 2006; 90:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebihara N, Ohashi Y, Uchio E, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther 2009; 25:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González-López JJ, López-Alcalde J, Morcillo Laiz R, et al. Topical cyclosporine for atopic keratoconjunctivitis. Cochrane Database Syst Rev 2012; :CD009078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yazu H, Shimizu E, Aketa N, et al. The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of severe atopic keratoconjunctivitis. Ann Allergy Asthma Immunol 2019; 122:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, et al. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology 2008; 115:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benaim D, Tétart F, Bauvin O, et al. Tacrolimus ointment in the management of atopic keratoconjunctivitis. J Fr Ophtalmol 2019; 42:e147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoang-Xuan T, Prisant O, Hannouche D, Robin H. Systemic cyclosporine A in severe atopic keratoconjunctivitis. Ophthalmology 1997; 104:1300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stumpf T, Luqmani N, Sumich P, et al. Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis. Cornea 2006; 25:1147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bielory L, Mongia A. Current opinion of immunotherapy for ocular allergy. Curr Opin Allergy Clin Immunol 2002; 2:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nivenius E, van der Ploeg I, Jung K, et al. Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis. Eye (Lond) 2007; 21:968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rikkers SM, Holland GN, Drayton GE, et al. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol 2003; 135:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zribi H, Descamps V, Hoang-Xuan T, et al. Dramatic improvement of atopic keratoconjunctivitis after topical treatment with tacrolimus ointment restricted to the eyelids. J Eur Acad Dermatol Venereol 2009; 23:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Amri AM. Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis. Am J Ophthalmol 2014; 157:280.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5550 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2008272" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clinical features of atopic keratoconjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1976238" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Atopic keratoconjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17940788" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Demographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20098903" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : [Atopic keratoconjunctivitis in patients of the pediatric dermatology ambulatory in a reference center].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20670816" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Atopic dermatitis and keratoconjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20720488" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Atopic keratoconjunctivitis and atopic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10197744" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Ocular surface disease in atopic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17873584" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16776679" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12623809" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9438492" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : T-cell cytokines in chronic allergic eye disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6144642" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Atopic corneal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15245362" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Atopic keratoconjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1923355" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Immunopathology of atopic keratoconjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1531476" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The T cell receptor in normal and inflamed human conjunctiva.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17873586" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical grading of atopic keratoconjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25682856" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Spontaneous corneal perforation associated with atopic keratoconjunctivitis: a case series and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33084033" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Systemic interventions for severe atopic and vernal keratoconjunctivitis in children and young people up to the age of 16 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31055787" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29610174" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Recalcitrant Atopic Keratoconjunctivitis in Children: A Case Report and Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3094562" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Evaluation of sodium cromoglycate and medrysone in the management of atopic keratoconjunctivitis: a double masked clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27086024" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9754182" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36151755" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Topical cyclosporine A 1 mg/ml for atopic keratoconjunctivitis: Five-year case series of 99 children and young people.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15019322" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16547328" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19441889" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22972132" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Topical cyclosporine for atopic keratoconjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30639466" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of severe atopic keratoconjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17900694" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30851973" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Tacrolimus ointment in the management of atopic keratoconjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9261317" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Systemic cyclosporine A in severe atopic keratoconjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17172887" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12582330" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Current opinion of immunotherapy for ocular allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16680103" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12614745" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Topical tacrolimus treatment of atopic eyelid disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18721214" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Dramatic improvement of atopic keratoconjunctivitis after topical treatment with tacrolimus ointment restricted to the eyelids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24439439" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
